Abstract
Background
To assess the long-term efficacy and the pattern of failure of concurrent chemoradiotherapy followed by high dose rate (HDR) brachytherapy for stage T2-3 N0-1 M0 esophageal carcinoma.
Methods
Forty-six patients with clinical stage T2-3 N0-1 M0 esophageal cancer received concurrent chemoradiotherapy followed by HDR brachytherapy. The chemotherapy regimen was a combination of cisplatin 60 mg/m2 on day 1 and fluorouracil 600 mg/m2 continuous infusion from days 1 to 4 during the first and last week of external-beam irradiation. Radiotherapy consisted of external beam to a total dose of 40–60 Gy (median, 50 Gy) and high dose rate brachytherapy to 8–24 Gy (median, 16 Gy) in 2–4 fractions. External beam was delivered to a field of the primary lesion and the involved nodal lesions. All patients were followed up for at least 5 years.
Results
The 5-year overall survival rate was 28%. The median survival duration was 22 months. The 5-year cause-specific survival rate was 34% and the median was 22 months. Persistent disease was found in 7 of 46 patients (15%). Of the 39 patients with initial complete tumor disappearance, locoregional failure occurred ultimately in 13 patients. The ultimate local control rate was 57% (26/46). Three patients were salvaged successfully with surgery. Four patients (9%) had regional recurrence out of the irradiated fields as first failure site. Four patients (9%) had recurrence 3 years or longer after treatment. Twelve patients had transient ulcers, which healed spontaneously within a few months. Massive esophageal bleeding, thought to be treatment related, occurred in 2 patients, leading to death. Severe late toxicity with esophageal ulceration was found in patients receiving a dose of 16–24 Gy via brachytherapy.
Conclusions
Concurrent chemoradiotherapy followed by HDR brachytherapy achieved long-term effective and curative results for stage T2-3 N0-1 M0 esophageal carcinoma. However, severe late toxicity was observed with 16–24 Gy via brachytherapy. We recommend a dose via HDR brachytherapy should be 12 Gy or less following concurrent chemoradiotherapy.
Similar content being viewed by others
References
JS Cooper MD Guo A Herskovic JS Macdonald JA Martenson M Al-Sarraf et al. (1999) ArticleTitleChemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG085-01) JAMA 281 1623–7 Occurrence Handle1:STN:280:DyaK1M3kvFagtw%3D%3D Occurrence Handle10235156 Occurrence Handle10.1001/jama.281.17.1623
S Hironaka A Ohtsu N Boku M Muto F Nagashima H Saito et al. (2003) ArticleTitleNonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any)M(0) squamous cell carcinoma of the esophagus Int J Radiat Oncol Biol Phys 57 425–33 Occurrence Handle12957254 Occurrence Handle10.1016/S0360-3016(03)00585-6
T Okawa T Dokiya M Nishio Y Hishikawa K Morita (1999) ArticleTitleMulti-institutional randomized trial of external radiotherapy with and without intraluminal brachytherapy for esophageal cancer in Japan. Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group Int J Radiat Oncol Biol Phys 45 623–8 Occurrence Handle1:STN:280:DyaK1Mvlt1Sntw%3D%3D Occurrence Handle10524414 Occurrence Handle10.1016/S0360-3016(99)00253-9
RK Sur CV Levin B Donde V Sharma L Miszczwk S Nag (2002) ArticleTitleProspective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma: an International Atomic Energy Agency study Int J Radiat Oncol Biol Phys 53 127–33 Occurrence Handle12007950 Occurrence Handle10.1016/S0360-3016(02)02702-5
LE Gaspar K Winter WI Kocha LR Coia A Herskovic M Graham (2000) ArticleTitleA phase I/II study of external beam radiation, brachytherapy, and concurrent chemoradiotherpy for patients with localized carcinoma of the esophagus (RTOG 9207): final report Cancer (Phila) 88 988–95 Occurrence Handle1:CAS:528:DC%2BD3cXhvFGhs70%3D
BD Minsky TF Pajak RJ Ginsberg TM Pisansky J Martenson R Komaki et al. (2002) ArticleTitleINT 0123 (Radiation Therapy Oncology Group 94-05) Phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy J Clin Oncol 20 1167–74 Occurrence Handle1:CAS:528:DC%2BD38XisVWmur4%3D Occurrence Handle11870157 Occurrence Handle10.1200/JCO.20.5.1167
A Yorozu T Dokiya Y Oki (1999) ArticleTitleHigh-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma Int J Radiat Oncol Biol Phys 45 271–5 Occurrence Handle1:STN:280:DyaK1MvhsFCrtA%3D%3D Occurrence Handle10487545 Occurrence Handle10.1016/S0360-3016(99)00184-4
InstitutionalAuthorNameInternational Union Against Cancer (2002) TNM classification of malignant tumors EditionNumber6th ed. Springer-Verlag New York
A Yorozu T Dokiya Y Oki T Suzuki (1999) ArticleTitleCurative radiotherapy with high-dose-rate brachytherapy boost for localized esophageal carcinoma: dose-effect relationship of brachytherapy with the balloon type applicator system Radiother Oncol 51 133–9 Occurrence Handle1:STN:280:DyaK1Mzmt1WrsA%3D%3D Occurrence Handle10435804 Occurrence Handle10.1016/S0167-8140(99)00040-7
G Calais E Dorval P Louisot R Bourlier V Klein S Chapet et al. (1997) ArticleTitleRadiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for stages IIB and III esophageal carcinoma: results of a pilot study Int Radiat Oncol Biol Phys 38 769–75 Occurrence Handle1:STN:280:ByiA1c3msVU%3D
S Ishikura K Nihei A Ohtsu N Boku S Hironaka K Mera et al. (2003) ArticleTitleLong-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus J Clin Oncol 21 2697–702 Occurrence Handle1:CAS:528:DC%2BD2cXptlCktLY%3D Occurrence Handle12860946 Occurrence Handle10.1200/JCO.2003.03.055
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yorozu, A., Toya, K. & Dokiya, T. Long-term results of concurrent chemoradiotherapy followed by high dose rate brachytherapy for T2-3 N0-1 M0 esophageal carcinoma. Esophagus 3, 1–5 (2006). https://doi.org/10.1007/s10388-006-0073-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10388-006-0073-9